Immunotherapy Archives

News and Trends 5 Sep 2022

CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy

CellOrigin Biotech (Hangzhou) Co., Ltd. and Qilu Pharmaceutical are to collaborate on strategic global collaborations to develop, manufacture and commercialize ‘off-the-shelf’ induced pluripotent stem cells (iPSC)-derived chimeric antigen receptor macrophages (CAR-iMAC) for cancer immunotherapy. Both companies will work on new drug development and commercialization, and will push CAR-iMAC pipelines forward to clinical trials. “Innovation, and […]

September 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 29 Aug 2022

Sanyou and KangaBio to collaborate on antibody drug development and innovation

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Shanghai KangaBio Co., Ltd. have reached an antibody drug licensing agreement. The subject of the agreement is a monoclonal antibody drug developed by Sanyou Biopharmaceuticals, which grants KangaBio an exclusive license to exploit the antibody for research, development, manufacturing and commercialization of immunotherapy products. Previously, KangaBio and Sanyou Biopharmaceuticals […]

August 29, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 25 Aug 2022

3T Biosciences launches with $40M financing

3T Biosciences wants to change the future of treatment for solid tumors and other immune-mediated diseases. And it exited from stealth today backed by $40 million in series A financing led by Westlake Village BioPartners with participation from Lightspeed Venture Partners. Proceeds from the financing will be used to help accelerate 3T Biosciences from a […]

August 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 24 Aug 2022

Northwest Biotherapeutics’ pediatric investigation plan approved by MHRA

Northwest Biotherapeutics, a biotech company developing DCVax personalized immune therapies for solid tumor cancers, has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its pediatric investigation plan (PIP). The development, regulatory review and regulatory approval of a PIP is a pre-requisite for application for approval of a new medicine for […]

August 24, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 18 Aug 2022

First patient on Innovative Cellular Therapeutics’ study looking at treating colorectal cancer

The first patient has been enrolled on a study to trial a treatment for relapsed or refractory metastatic colorectal cancer (R/R mCRC) in the U.S. Innovative Cellular Therapeutics (ICT), Inc. a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies made the announcement today (August 18). Tolerability The study […]

August 18, 2022 - 2 minutesmins - By Liza Laws

News and Trends 10 Aug 2022

Bone Therapeutics and Medsenic set to combine in share for share deal

Subject to the outcome of a shareholders’ meeting, Bone Therapeutics and Medsenic are set to combine their operations reducing risks and broadening portfolios. The companies announced they have signed a share for share binding contribution today (August 10) which will create new enterprise BioSenic. Brussels and Paris-based Bone Therapeutics is a cell therapy company that […]

August 10, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Aug 2022

Genmab and BioNTech expand collaboration to develop and commercialize immunotherapy candidates

A collaboration between Genmab and BioNTech to develop and commercialize immunotherapies for the treatment of cancer patients has been expanded. Under the expansion announced today (August 5), the companies will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint […]

August 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Aug 2022

Success across the board for C4X Discovery Holdings plc and its partnerships

Drug discovery company C4X Discovery Holdings plc released a report today (August 2) detailing the continued success of its relationship with partners across its portfolio. The company says it is happy to report it received its first milestone payment last month of €3 million ($3.1 million) from Sanofi under the out-licensing agreement for its IL-17A […]

August 2, 2022 - 3 minutesmins - By Liza Laws

More News! 29 Jul 2022

Cancer patients enrolled on study to predict immunotherapy response

An observational study has started enrolling patients with advanced/metastatic non-small cell lung cancer (NSCLC). Florida-based Nilogen Oncosystems made the announcement today (July 29) that those who are receiving immune checkpoint inhibitors in the standard of care will be registered for the study. Using advanced artificial intelligence and machine learning algorithms to discover biomarker signatures as […]

July 29, 2022 - 3 minutesmins - By Liza Laws

circulating tumor cells, cancer, clinical trials

News and Trends 28 Jul 2022

Kelun-Biotech announces joint license agreement with MSD for drug targeting solid tumors

Kelun-Biotech and MSD (Merck & Co.) have announced they are entering in a joint license agreement to develop a drug to treat solid tumors. The announcement was made yesterday (July 27) for the partnership to create the investigational antibody drug conjugate (ADC). Under the terms of the agreement, Kelun-Biotech, a clinical-stage biotech company focused on […]

July 28, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Jul 2022

Valo Therapeutics acquires PeptiCHIP technology to identify tumor antigens

Finnish immunotherapy company Valo Therapeutics Oy (ValoTx) has obtained exclusive licensing of intellectual property rights (IPR) from the University of Helsinki, Finland, for the institution’s PeptiCHIP technology. Following further validation by ValoTx, and the achievement of specific milestones, the IPR will transfer in full to the company. Valo said the deal will enable the rapid […]

July 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Jul 2022

Trial for drug targeting cancerous tumors begins in China

A phase 1 trial to investigate a drug for treating people with advanced malignant neoplasms has begun in China. HUTCHMED announced the trial of anti-CD47 monoclonal antibody HMPL-A83 on Friday (July 15). It is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and it is the company’s second large molecule drug candidate to […]

July 18, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy

Sanyou and KangaBio to collaborate on antibody drug development and innovation

3T Biosciences launches with $40M financing

Northwest Biotherapeutics’ pediatric investigation plan approved by MHRA

First patient on Innovative Cellular Therapeutics’ study looking at treating colorectal cancer

Bone Therapeutics and Medsenic set to combine in share for share deal

Genmab and BioNTech expand collaboration to develop and commercialize immunotherapy candidates

Success across the board for C4X Discovery Holdings plc and its partnerships

Cancer patients enrolled on study to predict immunotherapy response

Kelun-Biotech announces joint license agreement with MSD for drug targeting solid tumors

Valo Therapeutics acquires PeptiCHIP technology to identify tumor antigens

Trial for drug targeting cancerous tumors begins in China

Subscribe to our newsletter to get the latest biotech news!

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!